Technology
Health
Biotechnology

Neurocrine

$87.62
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$2.81 (3.31%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Neurocrine and other stocks, options, ETFs, and crypto commission-free!

About

Neurocrine Biosciences, Inc. operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. Read More The company product includes INGREZZA. Neurocrine Biosciences was founded by Kevin C. Gorman and Wylie W. Vale on January 1992 and is headquartered in San Diego, CA.

Employees
585
Headquarters
San Diego, California
Founded
1992
Market Cap
7.70B
Price-Earnings Ratio
485.16
Dividend Yield
0.00
Average Volume
862.71K
High Today
$87.70
Low Today
$84.97
Open Price
$85.03
Volume
444.33K
52 Week High
$126.98
52 Week Low
$64.72

Collections

Technology
Health
Biotechnology
Pharmaceutical
US
North America

News

Seeking Alpha14h

Neurocrine Biosciences: Rapid Pipeline Expansion Underway

Since my earlier article, Neurocrine Biosciences (NBIX) shares have retreated quite a bit off all time highs in September 2018. The safety scare was the first major selloff on elevated volume as an increase in reported deaths caused a panic, sending shares down over 10% one day in November.

55
Yahoo FinanceMar 15

CTLT or NBIX: Which Is the Better Value Stock Right Now?

CTLT vs. NBIX: Which Stock Is the Better Value Option? Investors interested in stocks from the Medical - Drugs sector have probably already heard of Catalent (CTLT) and Neurocrine Biosciences (NBIX). But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look. There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores syst...

75
Seeking AlphaMar 13

Neurocrine Biosciences May Have Something Interesting With NBI-74788

There's miles to go with NBI-74788's development, including more meaningful efficacy and safety data, but this could be a real contender in a multibillion-dollar opportunity.

16

Earnings

-$0.68
-$0.28
$0.12
$0.52
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
β€”
Actual
Expected Apr 29, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.